相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Estimated Cause-specific Survival Continues to Improve Over Time in Patients With Chondrosarcoma
Kyle R. Duchman et al.
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (2014)
3-Deazaneplanocin A (DZNep), an Inhibitor of S-Adenosylmethionine-dependent Methyltransferase, Promotes Erythroid Differentiation
Tohru Fujiwara et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
The Polycomb Protein Ezh2 Impacts on Induced Pluripotent Stem Cell Generation
Xiaolei Ding et al.
STEM CELLS AND DEVELOPMENT (2014)
Advanced chondrosarcomas: role of chemotherapy and survival
A. Italiano et al.
ANNALS OF ONCOLOGY (2013)
Polycomb complexes in stem cells and embryonic development
Luigi Aloia et al.
DEVELOPMENT (2013)
Inhibition of Enhancer of Zeste Homolog 2 (EZH2) Expression Is Associated With Decreased Tumor Cell Proliferation, Migration, and Invasion in Endometrial Cancer Cell Lines
Ramez N. Eskander et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2013)
Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity
X. Zhao et al.
LEUKEMIA (2013)
Pharmacological Reversal of Histone Methylation Presensitizes Pancreatic Cancer Cells to Nucleoside Drugs: In Vitro Optimization and Novel Nanoparticle Delivery Studies
Sau Wai Hung et al.
PLOS ONE (2013)
Cell Reprogramming Requires Silencing of a Core Subset of Polycomb Targets
Giulia Fragola et al.
PLOS GENETICS (2013)
EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis
Francesco Crea et al.
CANCER AND METASTASIS REVIEWS (2012)
TP53 Genomic Status Regulates Sensitivity of Gastric Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A (DZNep)
Lai Ling Cheng et al.
CLINICAL CANCER RESEARCH (2012)
Polycomb genes and cancer: Time for clinical application?
Francesco Crea et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2012)
EZH2 couples pancreatic regeneration to neoplastic progression
Jon Mallen-St Clair et al.
GENES & DEVELOPMENT (2012)
3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells
Tetsuhiro Chiba et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Clinical outcome of central conventional chondrosarcoma
Andrea Angelini et al.
JOURNAL OF SURGICAL ONCOLOGY (2012)
Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes
Karolina Holm et al.
MOLECULAR ONCOLOGY (2012)
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
Michael T. McCabe et al.
NATURE (2012)
New lysine methyltransferase drug targets in cancer
Tobias Wagner et al.
NATURE BIOTECHNOLOGY (2012)
Silencing of Kruppel-like factor 2 by the histone methyltransferase EZH2 in human cancer
H. Taniguchi et al.
ONCOGENE (2012)
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
Wei Qi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Histone lysine methylation and demethylation pathways in cancer
Radhika A. Varier et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2011)
The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML
Jianbiao Zhou et al.
BLOOD (2011)
S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition
Annette Hayden et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
(-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells
Subhasree Roy Choudhury et al.
CARCINOGENESIS (2011)
Polycomb EZH2 controls self-renewal and safeguards the transcriptional identity of skeletal muscle stem cells
Aster H. Juan et al.
GENES & DEVELOPMENT (2011)
Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer
Francesco Crea et al.
MOLECULAR CANCER (2011)
RNAi targeting EZH2 inhibits tumor growth and liver metastasis of pancreatic cancer in vivo
Yangchao Chen et al.
CANCER LETTERS (2010)
ESCs Require PRC2 to Direct the Successful Reprogramming of Differentiated Cells toward Pluripotency
Carlos F. Pereira et al.
CELL STEM CELL (2010)
Enhancer of Zeste Homolog 2 Promotes the Proliferation and Invasion of Epithelial Ovarian Cancer Cells
Hua Li et al.
MOLECULAR CANCER RESEARCH (2010)
Epigenetic modifications as therapeutic targets
Theresa K. Kelly et al.
NATURE BIOTECHNOLOGY (2010)
An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB
Junxia Min et al.
NATURE MEDICINE (2010)
The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer
J. Yu et al.
ONCOGENE (2010)
Histone H3K27 methyltransferase Ezh2 represses Wnt genes to facilitate adipogenesis
Lifeng Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
EZH2 Is Essential for Glioblastoma Cancer Stem Cell Maintenance
Mario-Luca Suva et al.
CANCER RESEARCH (2009)
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation
Tina Branscombe Miranda et al.
MOLECULAR CANCER THERAPEUTICS (2009)
BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A
Julian Puppe et al.
BREAST CANCER RESEARCH (2009)
Regulation of Pancreatic Tumor Cell Proliferation and Chemoresistance by the Histone Methyltransferase Enhancer of Zeste Homologue 2
Andrei V. Ougolkov et al.
CLINICAL CANCER RESEARCH (2008)
Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation
Satoshi Fujii et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Repression of E-cadherin by the polycomb group protein EZH2 in cancer
Q. Cao et al.
ONCOGENE (2008)
Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells
Jing Tan et al.
GENES & DEVELOPMENT (2007)
EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast
IM Bachmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Establishment and characterization of a continuous human chondrosarcoma cell line, ch-2879:: Comparative histologic and genetic studies with its tumor of origin
R Gil-Benso et al.
LABORATORY INVESTIGATION (2003)
The polycomb group protein EZH2 is involved in progression of prostate cancer
S Varambally et al.
NATURE (2002)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)
分享论文
